Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03961932 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetics of Linzagolix in Female Subjects With Normal and Impaired Renal Function
A Phase 1 study, sponsored by ObsEva.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT03961932 is a Phase 1 study that has completed, run by ObsEva. The registered enrollment target is 33 participants.
The verdict
NCT03961932, a Phase 1 study, has completed, sponsored by ObsEva.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the pharmacokinetics (PK) of linzagolix in subjects with varying degrees of impaired renal function compared to matched control subjects with normal renal function
Interventions
- DRUG Linzagolix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2019-05-15 |
| Est. Completion | 2020-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03961932
The ClinicalTrials.gov registry entry for NCT03961932 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ObsEva, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Linzagolix is the first listed.
NCT03961932 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03961932 about?
NCT03961932 is a clinical study titled "Safety and Pharmacokinetics of Linzagolix in Female Subjects With Normal and Impaired Renal Function". The primary objective of this study is to assess the pharmacokinetics (PK) of linzagolix in subjects with varying degrees of impaired renal function compared to matched control subjects with normal renal function
What is the current status of trial NCT03961932?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2019-05-15. Estimated completion is 2020-01-31.
What interventions are being tested in trial NCT03961932?
The interventions under investigation include: Linzagolix (DRUG).
Who is sponsoring clinical trial NCT03961932?
This trial is sponsored by ObsEva, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.